← Back to Search

Synthetic Tissue Substitute

First-In-Man Study for an Ophthalmic Synthetic Tissue Substitute

N/A
Waitlist Available
Research Sponsored by CorNeat Vision Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the safety of the CorNeat EverPatch, a synthetic cover for eye implants and glaucoma shunts. It targets patients needing these implants concealed, especially during certain procedures. The patch works by covering and protecting the implants, integrating with the eye's tissue.

Eligible Conditions
  • Glaucoma
  • Tissue Necrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of treatment-related adverse events
Secondary study objectives
Conjunctival integrity
Stability in patch dimensions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Synthetic Tissue SubstituteExperimental Treatment1 Intervention
Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants

Find a Location

Who is running the clinical trial?

CorNeat Vision Ltd.Lead Sponsor
3 Previous Clinical Trials
62 Total Patients Enrolled
1 Trials studying Glaucoma
12 Patients Enrolled for Glaucoma
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top